Whalesbook
Sun Pharma ne ekdum record breaking deal ki hai! Organon & Co. ko $11.75 Billion mein khareed liya hai. Is se yeh Indian pharma company duniya ki top 25 pharma makers mein officially shamil ho jayegi. Reports ke according, is acquisition se Sun Pharma ki saal bhar ki revenue lagbhag $12.4 Billion ho jayegi. Aur toh aur, ab company ke portfolio mein women's health aur biosimilars jaise naye aur important areas bhi jud jayenge, jahan Organon pehle se strong hai. Lekin, ek badi situation yeh hai ki Organon par pehle se $8.6 Billion ka debt hai, jo Sun Pharma ke liye ek bada challenge banne wala hai. Sun Pharma toh pehle se kam debt wali company thi, toh yeh ek significant shift hai.
Market Reaction Kaisa Raha?
Jab yeh news aayi, toh Sun Pharma ke shares mein 7% se bhi zyada ki tezi dekhi gayi thi! Intraday mein stock ₹1,766.90 tak pahunch gaya tha. Lagta hai investors ko yeh deal aur company ke badhte scale par kaafi bharosa hai. Organon ke shares bhi announcement wale din 17% upar bhage the. Deal $14 per share ke hisaab se hui hai. Par, itna bada amount aur saath mein yeh debt future mein kuch sawal utha sakta hai. Deal ka target hai ki transaction ke baad net debt-to-EBITDA ratio 2.3x rahega. Sun Pharma ka pehle debt-to-equity ratio toh sirf 6.7% tha.
Pharma Industry Ka Trend
Yeh acquisition pharmaceutical industry mein chal rahe M&A (Mergers & Acquisitions) ke trend se bilkul match karta hai. Pharma companies apne business ko consolidate kar rahi hain aur commercial-stage assets par zyada focus kar rahi hain. Sun Pharma, Organon ke established brands aur biosimilar capabilities ka use karke apni presence global markets mein aur strong karna chahti hai. Indian pharma sector toh waise bhi 9-11% per annum ke hisaab se grow kar raha hai FY2026 mein. Sun Pharma ka goal hai ki woh Teva aur Viatris jaisi badi global companies ke barabar aa sake.
Debt Aur Integration Ka Risk
Deal mein strategic benefits toh hain, par iske saath kuch bade risks bhi jude hain. Organon ka $8.6 Billion ka debt sunne mein hi bahut zyada lag raha hai, jiske wajah se debt-to-equity ratio 1149.5% ho gaya hai. Yeh Sun Pharma ki conservative financial policy se kaafi alag hai. Analysts keh rahe hain ki Organon ki sales pichhle 4 saal se flat hain aur kuch important products ke patents bhi expire hone wale hain. Plus, Organon ne 2024 mein $1.2 Billion mein Dermavant bhi acquire kiya tha, toh integration ko lekar aur unexpected costs ko lekar bhi worries hain. Organon ka valuation dekha jaye toh P/E ratio 15.86x hai, jo Sun Pharma ke 38-40x aur sector average 33.3x se kaafi kam hai. JM Financial jaise kuch analysts ko doubt hai ki Organon ka growth itna nahi hoga ki Sun Pharma ne jo premium diya hai woh justify ho sake. Founder Dilip Shanghvi, jo debt avoid karne ke liye jaane jaate hain, ab Organon ke cash flow se yeh bada debt kam karne ki challenge face karenge.
Aage Ka Outlook
Is sab risks ke bawajood, kuch analysts abhi bhi positive hain. Motilal Oswal ne toh 'Buy' rating maintain ki hai aur target price ₹2,025 rakha hai. Unko lagta hai ki Sun Pharma acquired businesses ko successfully scale up kar sakti hai aur Organon ke operations ko improve kar sakti hai. Sun Pharma ko expect hai ki deal ke baad combined EBITDA aur annual free cash flow $3.7 Billion se zyada hoga, jo debt reduction mein help karega. Organon ka biosimilar segment toh Q1 2026 mein 23% grow kar raha hai, jo ek achha growth opportunity hai. Magar, akhir mein sab kuch culture merge karne, operations ko smooth banane aur Organon ke bade debt ko manage karne par depend karega. Yahi decide karega ki yeh record deal Sun Pharma ke liye lasting value banayegi ya sirf ek mahangi expansion reh jayegi.